Navigation Links
India Fast Become Prime Location for Clinical Trials, but Vigilance Called for

India is fast becoming a prime location for clinical trials for many pharmaceutical giants//, observers say.

Pfizer, BristolMyers Squibb, GlaxoSmithkline, Eli Lilly are among those big firms that conduct the trials in the country.

Currently over 226 clinical trials approved by the U.S. Food and Drug Administration (FDA) are in India.

Faced with the increasing costs of clinical trials and a shortage of willing participants at home, western drug companies are looking at off-shoring the trials to the third world.

India has perhaps the world's largest patient pool, it is pointed out. Moreover, it may be easy to pick out those who may not be taking any other medicine.

But the main consideration is costs — industry watchers say drug companies may save up to 50% of the costs of new drug development by conducting trials in India.

Big cities are favorite spots for these trials, with Delhi having 76 trials, Mumbai 86, Chennai 50 and Bangalore 64, it is reported.

Many clinical research organizations (CROs) have sprouted up, offering to carry out such trials. They are getting business worth up to 120 million US dollars a year. It is expected that clinical trials estimated to cost two billion dollars could end up in India by 2010.

The Center has made changes in laws and regulations to accommodate the clinical trial boom.

Apart from changes in patent laws, which will protect data confidentiality, initial or phase-1 trials are also permitted.

A Framework for Good Clinical Practices has also been announced. In the budget for 2007-08, the service tax on clinical trials was done away with.

However, many doubt whether India's top regulatory body, the Drug Controller General of India, is technically equipped to cope with the influx.

In recent years, there has been a spate of failures of clinical trials with many of the top pharma compani es being forced to withdraw drugs after adverse reports. While Bristol-Myers Squibb terminated a new diabetes drug, Astra Zeneca halted work on a new drug for stroke patients. And Pfizer did so with its cholesterol-reducing Torcetrapib.

They all pull out only on realizing irreversible damage has been caused to the subjects. But no one will compensate them or their families.

Necessary measures to protect the health of the Indian citizens should be put in place first, urge activists. That is far more important than earning dollars, they stress.
'"/>




Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. AIDS Disaster in India is Imminent
3. Indian Prime Minister has successful Knee Replacement Surgery
4. International community warns India on HIV situation
5. India takes on foot-and-mouth disease by vaccinating animals
6. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
7. India to benefit from pharma companies move
8. Healthcare sector is now a multi billion-dollar industry in India
9. The World Bank funds private Hospital in India
10. Parke-Davis (India) runs into rough weather – Court orders attachment of asset
11. Indian Doctor granted US patent on organ regeneration
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... , February 23, 2017 ... on the global market for intraoperative imaging, excerpts ... valued at US$ 513.9 million. According to the ... surging on the grounds of increasing adoption of ... field of diagnostic imaging for neurosurgeries. The world,s ...
Breaking Medicine Technology: